{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:13:30Z","timestamp":1785795210230,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.alit.2021.12.002","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T14:50:59Z","timestamp":1645973459000},"page":"185-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Drug allergy and non-HIV immune reconstitution inflammatory syndrome"],"prefix":"10.1016","volume":"71","author":[{"given":"Hirohiko","family":"Sueki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Mizukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2021.12.002_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00005792-200205000-00005","article-title":"Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy","volume":"81","author":"Shelburne","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.alit.2021.12.002_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2332\/allergolint.10-RAI-0260","article-title":"Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruptions and those under immunosuppressive therapy","volume":"59","author":"Shiohara","year":"2010","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2021.12.002_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/2013.jamadermatol.503","article-title":"Immune reconstitution reactions in human immunodeficiency virus-negative patients: report of a case and review of the literature","volume":"149","author":"Sharschimidt","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/QCO.0b013e32832d7aff","article-title":"Immune reconstruction inflammatory syndrome in non-HIV immunocompromised patients","volume":"22","author":"Sun","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.alit.2021.12.002_bib5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/522182","article-title":"Immune reconstitution syndrome and exacerbation of infection after pregnancy","volume":"45","author":"Singh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.alit.2021.12.002_bib6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s100960100507","article-title":"Immunorestitution diseases in patients not infected with HIV","volume":"20","author":"Cheng","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.alit.2021.12.002_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1346-8138.14074","article-title":"Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients","volume":"45","author":"Sueki","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.resinv.2019.11.001","article-title":"Immune reconstitution inflammatory syndrome in the lung in non-human immunodeficiency virus patients","volume":"58","author":"Fujita","year":"2020","journal-title":"Respir Investig"},{"key":"10.1016\/j.alit.2021.12.002_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000500945","article-title":"Severe cutaneous adverse reactions during tapering of high-dose systemic steroid therapy for autoimmune diseases: implications for non-HIV immune reconstitution inflammatory syndrome","volume":"11","author":"Sueki","year":"2019","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.alit.2021.12.002_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000441280","article-title":"Drug hypersensitivity: how drugs stimulate T cells via pharmacological interaction with immune receptors","volume":"168","author":"Pichler","year":"2015","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.alit.2021.12.002_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5415\/apallergy.2016.6.2.77","article-title":"T-cell-mediated hypersensitivity: immune mechanisms and their clinical relevance","volume":"6","author":"Yun J Cai","year":"2016","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.alit.2021.12.002_bib13","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/all.13765","article-title":"Immune pathomechanism and classification of drug hypersensitivity","volume":"74","author":"Pichler","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2021.12.002_bib14","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.alit.2021.12.002_bib15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jdermsci.2017.08.007","article-title":"A\u00a0docking model of dapsone bound to HLA-B\u221713:01 explains the risk of dapsone hypersensitivity syndrome","volume":"88","author":"Watanabe","year":"2017","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.alit.2021.12.002_bib16","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1172\/JCI113798","article-title":"Anticonvulsant hypersensitivity syndrome. In\u00a0vitro assessment of risk","volume":"82","author":"Shear","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.alit.2021.12.002_bib17","first-page":"1108","article-title":"Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpes virus 6","volume":"134","author":"Suzuki","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archderm.134.9.1113","article-title":"Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6","volume":"134","author":"Tohyama","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and hypersensitivity syndrome (Drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.alit.2021.12.002_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/1346-8138.12770","article-title":"Sequelae in 145 patients with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR)","volume":"42","author":"Kano","year":"2015","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib21","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archdermatol.2009.195","article-title":"Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome","volume":"145","author":"Asano","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/archderm.140.2.183","article-title":"Association between anticonvulsant hypersensitivity syndrome and human herpes virus 6 reactivation and hypogammaglobulinemia","volume":"140","author":"Kano","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib23","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2021.12.002_bib24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/cea.13252","article-title":"Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruption","volume":"48","author":"Ushigome","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2021.12.002_bib25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1398-9995.2007.01553.x","article-title":"Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption","volume":"62","author":"Kano","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2021.12.002_bib26","first-page":"463","article-title":"[Pneumonia in drug-induced hypersensitivity syndrome: focusing on Pneumocystis pneumonia]","volume":"127","author":"Kano","year":"2017","journal-title":"[Jap J Dermatol]"},{"key":"10.1016\/j.alit.2021.12.002_bib27","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.jaad.2010.11.057","article-title":"A\u00a0review of DRESS-associated myocarditis","volume":"66","author":"Bourgeois","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2169\/internalmedicine.40.331","article-title":"Allopurinol hypersensitivity syndrome associated with systemic cytomegalovirus infection and systemic bacteremia","volume":"40","author":"Arakawa","year":"2001","journal-title":"Intern Med"},{"key":"10.1016\/j.alit.2021.12.002_bib29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/Drug reaction with eosinophilia and systemic symptoms (DRESS). An update in 2019","volume":"68","author":"Shiohara","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2021.12.002_bib30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/17425255.2017.1297422","article-title":"Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"13","author":"Shiohara","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.alit.2021.12.002_bib31","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2018.08.052","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease","volume":"80","author":"Mizuakwa","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2133.2006.07238.x","article-title":"Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease","volume":"155","author":"Kano","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jdcr.2015.04.017","article-title":"Detection of cytomegalovirus in the gastric ulcer of a patient with drug-induced hypersensitivity syndrome","volume":"1","author":"Kagoyama","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.alit.2021.12.002_bib34","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41598-020-79397-6","article-title":"Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events","volume":"11","author":"Matsukane","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.alit.2021.12.002_bib35","doi-asserted-by":"crossref","first-page":"117788","DOI":"10.1016\/j.lfs.2020.117788","article-title":"The role of biomarkers in diagnosis of COVID-19 -A systematic review","volume":"254","author":"Kermali","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.alit.2021.12.002_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijid.2020.08.078","volume":"100","author":"Mizukawa","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.alit.2021.12.002_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recent marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jdermsci.2020.09.009","article-title":"The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018","volume":"100","author":"Sunaga","year":"2020","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.alit.2021.12.002_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1600-0404.2008.01090.x","article-title":"Glucocorticoid increase CD4+ CD25high cell percentage and Foxp3 expression in patient with multiple sclerosis","volume":"119","author":"Braitch","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.alit.2021.12.002_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clim.2007.12.010","article-title":"CD4+ CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids","volume":"127","author":"Azab","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.alit.2021.12.002_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2567.2004.01869.x","article-title":"Normal human Pregnancy is associated with an elevation in immune suppressive CD25+ CD4+ regulatory T-cell subset","volume":"112","author":"Somerset","year":"2004","journal-title":"Immunology"},{"key":"10.1016\/j.alit.2021.12.002_bib42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archderm.141.5.601","article-title":"Hormonal effect on psoriasis in pregnancy and post partum","volume":"141","author":"Murase","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/dom.12610","article-title":"Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas","volume":"18","author":"Deacon","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.alit.2021.12.002_bib44","doi-asserted-by":"crossref","first-page":"107503","DOI":"10.1016\/j.pharmthera.2020.107503","article-title":"Dipeptidyl peptidase 4 inhibitors and their potential modulatory functions","volume":"209","author":"Shao","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.alit.2021.12.002_bib45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.it.2008.02.010","article-title":"Revisiting old acquaintance: CD26 and its molecular mechanisms in T cell function","volume":"29","author":"Ohnuma","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.alit.2021.12.002_bib46","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2021.12.002_bib47","article-title":"Neutrophil to lymphocyte ratio is predictive of severe complications and mortality in patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: a retrospective longitudinal observation study","author":"Sugiyama","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib48","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaad.2012.10.017","article-title":"Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution","volume":"68","author":"Ushigome","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib49","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.alit.2021.12.002_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.13011","article-title":"From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation","volume":"1417","author":"Bacchetta","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.alit.2021.12.002_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semcancer.2019.01.006","article-title":"Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis","volume":"64","author":"Kumar","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.alit.2021.12.002_bib52","first-page":"1841","article-title":"[Analysis of immune checkpoint inhibitor-induced cutaneous adverse events]","volume":"131","author":"Watanabe","year":"2021","journal-title":"[Jap J Dermatol]"},{"key":"10.1016\/j.alit.2021.12.002_bib53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib54","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib55","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J\u00a0Am Acad Dermtatol"},{"key":"10.1016\/j.alit.2021.12.002_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.02.044","article-title":"Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab","volume":"131","author":"Watanabe","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.alit.2021.12.002_bib57","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.jaad.2021.03.122","article-title":"Immune checkpoint inhibitor-related Stevens-Johnson syndrome\/toxic epidermal necrolysis-like reactions","volume":"85","author":"Choi","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.12.002_bib58","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1111\/jdv.16872","article-title":"Characteristic pathological features of keratinocyte death in a case of Stevens-Johnson syndrome manifested by an immune checkpoint inhibitor","volume":"35","author":"Kimura","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2021.12.002_bib59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11904-009-0022-z","article-title":"Management of patients with immune reconstitution inflammatory syndrome","volume":"6","author":"Marais","year":"2009","journal-title":"Curr HiV\/AIDS Rep"},{"key":"10.1016\/j.alit.2021.12.002_bib60","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/nm1108-1155","article-title":"Graft-versus-host disease: suppression by statins","volume":"14","author":"Broady","year":"2008","journal-title":"Nat Med"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893021001611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893021001611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:13:02Z","timestamp":1761156782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893021001611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1323893021001611"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2021.12.002","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug allergy and non-HIV immune reconstitution inflammatory syndrome","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2021.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Allergology. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}